All Type of News
Will BMS and Gilead divide hepatitis C treatment market?
BMS and Gilead have drawn a picture to divide the domestic hepatitis C treatment market.
According to the industry, the Ministry of Health and Welfare decided to register Sovaldi(generic name: sofosbuvir) and Harvon...
Multinational company’s annual average sales per employee were KRW 740 million
Annual sales per a person working for a multinational pharmaceutical company branched in Korea were estimated approximately at KRW 740 million.
It was observed Genzyme Korea had the most in the category with KRW 1.48...
10 healthcare personnel successfully enter 20th National Assembly
At the 20th General Election for the National Assembly, the total 10 healthcare personnel successfully entered the National Assembly.
According to the 2016 20th National Assembly election result on the 13th, 10(7 di...
Daiichi Sankyo, “Olmesartan’s removal of insurance benefit is not revocation of approval”“The decision is only removal from the insurance benefit, not revocation of approval. We will continue adjusting domestic actions with the Ministry of Food and Drug Safety.”
Wh...
|
Mental war among domestic companies facing Viread’s salt-modified products
While the gigantic hepatitis B therapy, ‘Viread(tenofovir disoproxil fumarate)’ is expected to be expired in its substance patent next year, competition among domestic companies have already started over follow-up pro...
Pfizer files lawsuit of compensation for damage against CJ and Samjin
It is now compensation for damage. Pfizer which succeeded in defending the ‘Lyrica’ use patent has decided its next move.
Pfizer Pharmaceuticals Korea filed a lawsuit of compensation for damage about usage of the Ly...
Pharmaceutical industry produced KRW 100 billion sales products last year
It was observed 5 gigantic blockbuster products of KRW 100 billion sales were produced in the pharmaceutical industry last year.
Moreover, 3 companies including Hanmi Pharm, Yuhan Corporation and Jeil Pharmaceutical ...
Green Cross’s Hunterase approved to conduct Phase 2 clinical trials in USGreen Cross’s rare disease therapies will challenge the U.S. market.
On the 12th, Green Cross(CEO Eun-cheol Huh) announced recent acquisition of approval to start Phase 2 clini...
|
Amgen collected domestic licenses of 3 biomedicines from GSKAmgen, which officially established a Korean branch, collected domestic licenses of 3 biomedicines that were handed to GSK. They are blockbuster drugs which globally recorded US...
|
4th NOAC ‘Lixiana’ landed in 4 of ‘Big 5’ hospitals
A series of news about the 4th NOAC ‘Lixiana(edoxaban)’ to land in general hospitals have continuously followed.
According to the industry concerned on the 13th, Lixiana, the new oral anti-coagulant(NOAC) jointly so...
